Roche's Kadcyla cleared in Japan, endorsed for approval in EU

09/22/2013 | (U.K.)

Roche Holding and ImmunoGen's Kadcyla was endorsed for approval by the European Medicine Agency's Committee for Medicinal Products for Human Use as a therapy for HER2-positive breast cancer when patients have previously been treated with taxane-based chemotherapy and Herceptin. The drug, which contains Herceptin's monoclonal antibody and ImmunoGen's DM1 cytotoxic agent, was approved in Japan.

View Full Article in: (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Chief Executive Officer
UCare Minnesota
Minneapolis, MN
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC